SEC Form 4 · accession 0001209191-15-067163

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Aug 19, 2015

Accepted (ET)

Aug 20, 2015 · 6:02 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Aug 19, 2015	M	10,400	$35.64	A	355,684	D
Common Stock^F2,F3	Aug 19, 2015	S	2,098	$138.44	D	353,586	D
Common Stock^F2,F4	Aug 19, 2015	S	3,802	$139.39	D	349,784	D
Common Stock^F2,F5	Aug 19, 2015	S	1,700	$140.61	D	348,084	D
Common Stock^F2,F6	Aug 19, 2015	S	2,800	$141.38	D	345,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F7	$35.64	Aug 19, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	240,000	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $138.44 (range $137.88 to $138.87).
F4Open market sales reported on this line occurred at a weighted average price of $139.39 (range $138.93 to $139.91).
F5Open market sales reported on this line occurred at a weighted average price of $140.61 (range $140.03 to $141.00).
F6Open market sales reported on this line occurred at a weighted average price of $141.38 (range $141.04 to $141.92).
F7Fully vested.